Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 62-year-old man with New York Heart Association class II heart failure with reduced ejection fraction is evaluated in the clinic. He is currently treated with lisinopril, metoprolol succinate, and spironolactone. His symptoms have persisted despite maximal tolerated doses of his current regimen. The physician plans to transition the patient from lisinopril to sacubitril-valsartan. His current blood pressure is 118/75 mm Hg, and his heart rate is 68/min. Laboratory studies show a serum potassium of 4.3 mEq/L and a serum creatinine of 1.1 mg/dL. Which of the following are required steps for appropriate treatment adaptation and ongoing monitoring in this patient? (Select all that apply)

  1. Ensure a minimum 36-hour washout period between the last dose of lisinopril and the first dose of sacubitril-valsartanAnswer
  2. B
    Assess therapeutic response by measuring serum B-type natriuretic peptide (BNP) levels four weeks after initiation
  3. Reassess serum potassium and creatinine levels within 1 to 2 weeks after starting the new medicationAnswer
  4. D
    Order a transthoracic echocardiogram 72 hours after initiation to evaluate acute changes in left ventricular ejection fraction
  5. E
    Continue lisinopril at a reduced dose for one week alongside sacubitril-valsartan to prevent rebound hypertension during titration

Answer

The correct steps are ensuring a 36-hour washout period after lisinopril discontinuation and reassessing serum potassium and creatinine within 1 to 2 weeks.
The correct sequence for transitioning a patient from an ACE inhibitor to an angiotensin receptor-neprilysin inhibitor (ARNI) involves two critical safety steps. First, because both ACE inhibitors and neprilysin inhibitors increase bradykinin levels, there is a substantial risk of severe angioedema if they are used simultaneously or in rapid succession. Consequently, guidelines strictly mandate a 36-hour washout period after the final dose of the ACE inhibitor before the first dose of the ARNI. Second, because ARNIs contain an angiotensin II receptor blocker (valsartan), they can precipitate acute kidney injury and hyperkalemia by altering renal efferent arteriolar tone. This risk is further elevated in patients concurrently taking a mineralocorticoid receptor antagonist like spironolactone. Therefore, re-evaluating serum creatinine and potassium levels 1 to 2 weeks after initiation is the standard of care.

Step-by-Step Solution

1
Identify the clinical goal and medication transition.
The patient is being switched from an ACE inhibitor (lisinopril) to an ARNI (sacubitril-valsartan) for symptomatic HFrEF.
Understanding the specific drug classes is essential for recognizing contraindications and required monitoring.
2
Determine the necessary safety precautions for initiation.
A 36-hour washout period is required between stopping the ACE inhibitor and starting the ARNI.
Simultaneous inhibition of ACE and neprilysin leads to excessive bradykinin accumulation, significantly increasing the risk of angioedema.
3
Select appropriate follow-up laboratory monitoring.
Serum potassium and creatinine must be checked 1 to 2 weeks after starting.
The valsartan component can reduce GFR and promote potassium retention, which is compounded by the patient's concurrent spironolactone use.
4
Rule out inappropriate tests and monitoring strategies.
BNP measurement and acute echocardiography are rejected.
Sacubitril inhibits BNP breakdown (making BNP levels falsely high), and acute imaging does not reflect long-term myocardial reverse remodeling.

Key Concept

Transitioning from an ACE inhibitor to an ARNI requires a 36-hour washout to prevent angioedema. Subsequent monitoring must include a basic metabolic panel within 1-2 weeks, and NT-proBNP (not BNP) should be used if biomarker tracking is desired.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic